In a retrospective study of 700 patients with culture-positive tuberculosis (TB), relapse rates were found to be significantly higher in HIV-infected patients compared to HIV-uninfected patients following a rifamycin-based regimen.
Genomic instability?the rearrangement of chromosomes or an abnormal number of chromosomes?is a hallmark of many human cancers.
A new vaccine aimed at preventing cervical cancer is nearly 100 percent effective against the two types of the human papillomavirus (HPV) responsible for most cases of cervical cancer?strains 16 and 18.
Vical Incorporated (Nasdaq:VICL) today announced that a measles DNA vaccine formulated with the company’s Vaxfectin? adjuvant elicited protective levels of neutralizing antibodies in juvenile (1 ? 2 year old) nonhuman primates confirmed by complete protection following challenge more than one year after vaccination, and sterilizing immunity as evidenced by no clinical signs of disease and no detectable virus after challenge.
Veterinarians who work with birds are at increased risk for infection with avian influenza virus and should be among those with priority access to pandemic influenza vaccines and antivirals, according to a study conducted by researchers in the University of Iowa College of Public Health.
Scientists at the Southwest Foundation for Biomedical Research have developed a new tool in the battle against a potential biological weapon, Lassa fever, which kills several thousand people each year and leaves thousands more with disabilities such as deafness and liver damage.
Adults who have recovered from the potentially deadly H5N1 strain of avian influenza may hold the key to future treatments for the virus, according to an international team of researchers.
A new study conducted by researchers from the University of Verona and the Institute G. Gaslini in Genova, Italy, confirms the pivotal role played by Cytomegalovirus infection in the pathogenesis of atherosclerosis.
New research conducted at the Uniformed Services University of the Health Sciences (USU) suggests that it may be possible to develop a vaccine that protects against the myriad strains of the HIV virus.
Using antibodies derived from immune cells from recent human survivors of H5N1 avian influenza to successfully treat H5N1-infected mice as well as protect them from an otherwise lethal dose of the virus, revealed by researchers.